Objective: Little is known about the natural history of isolated gastrocnemial and soleal vein thrombosis (IGSVT), and recommendations for treatment and follow-up are therefore anecdotal. This study sought to determine the rates of venous thromboembolism (VTE) progression and resolution and the effect of antithrombotic therapy in patients with IGSVT.
Methods: A vascular laboratory database was queried from January 2002 to December 2006 to identify patients with duplex-diagnosed IGSVT and follow-up duplex scan studies. Duplex scan examinations were reviewed to determine rates of resolution and development of new ipsilateral and contralateral VTE. Records were reviewed for comorbid conditions, VTE risk factors, anticoagulation therapy, the effect of anticoagulation on resolution of IGSVT, and diagnosis of pulmonary embolism (PE) confirmed by computed tomographic angiography.
Results: Patients with at least one follow-up duplex scan study were included in our analysis. Sixty-five limbs with isolated IGSVT were identified in 57 patients with follow-up duplex scans (mean, 2.75 studies per patient; mean follow-up, 113 days). Twenty patients (35%) received therapeutic anticoagulation after the IGSVT diagnosis. There were seven PEs, two on the same day as initial IGSVT diagnosis, and two within 1 week of diagnosis. IGSVT resolution rates by Kaplan-Meier analysis at 1 and 3 months were 20% and 41%, respectively. Eleven patients (19%) developed additional ipsilateral deep venous thrombosis (DVT; three axial calf vein thromboses and five proximal DVT) or contralateral DVT (one axial calf vein thrombosis [CVT], one IGSVT, and one proximal DVT) during follow-up. Of the eight patients who developed additional ipsilateral DVT, five also developed concurrent contralateral DVT. Overall, 14% of patients developed contralateral DVT. Median time to development of additional DVT was 10 days. Therapeutic anticoagulation was associated with DVT resolution. However, VTE recurrence was not significantly affected by age, gender, anticoagulation, oral contraceptives, known hypercoagulable states, or comorbidities (smoking, cancer, trauma, postsurgical status, renal failure, hyperlipidemia, diabetes, or cardiopulmonary abnormalities; P > .05).
Conclusions: Isolated calf muscular vein thrombosis is associated with PE and a significant incidence of VTE progression. Therapeutic anticoagulation is associated with DVT resolution, but its effect on VTE recurrence was not demonstrated. Untreated patients with IGSVT should receive follow-up bilateral lower extremity venous duplex scans within 10 days of diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvsv.2012.04.001 | DOI Listing |
Paediatr Drugs
January 2025
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients.
Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the European Union Clinical Trials Register for English-language records from the establishment of the database up to October 17, 2023.
Aliment Pharmacol Ther
January 2025
Gastro Unit, Copenhagen University Hospital, Hvidovre, Denmark.
Phlebology
January 2025
Department of Clinical Laboratory, The Second Hospital Affiliated Fujian Medical University, Quanzhou, China.
Background: Deep vein thrombosis (DVT) of the lower limb is a significant clinical challenge with the potential for recurrence, which can lead to increased morbidity and reduced quality of life.
Methods: A retrospective case-control study was conducted involving 367 patients diagnosed with lower limb DVT from June 2020 to June 2023. Patients were categorized into a recurrence group ( = 121) and a non-recurrence group ( = 246) based on DVT occurrence.
Thromb J
January 2025
College of engineering and computer sciences, Jazan University, Jazan, Saudi Arabia.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), continues to pose significant clinical challenges despite advancements in medical care. Artificial intelligence (AI) presents promising opportunities to enhance the diagnosis, prediction, and management of VTE. This review examines the transformative potential of AI in thrombosis care, highlighting both the potential benefits and the challenges that need to be addressed.
View Article and Find Full Text PDFJ Neurointerv Surg
January 2025
Department of Neurointerventional Surgery, Queen's Medical Center, Honolulu, Hawaii, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!